Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Exemestane
Drug ID BADD_D00861
Description Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
Indications and Usage For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Marketing Status Prescription
ATC Code L02BG06
DrugBank ID DB00990
KEGG ID D00963
MeSH ID C056516
PubChem ID 60198
TTD Drug ID D0D2VS
NDC Product Code 62157-091; 51991-005; 59057-007; 73377-132; 64918-0621; 50090-5193; 52128-134; 63629-2056; 59057-008; 69097-316; 0009-7663; 62756-981; 68382-383; 64181-0005; 0832-0595; 44278-025; 0378-5001; 65427-030; 71921-190; 46439-8746; 49386-026; 65162-240; 53104-7666; 47781-108; 59762-2858; 0054-0080; 65129-1217; 70771-1374; 64918-0622; 65089-0046
Synonyms exemestane | examestane | 6-methyleneandrosta-1,4-diene-3,17-dione | FCE 24304 | FCE-24304 | Aromasil | Aromasin | Aromasine
Chemical Information
Molecular Formula C20H24O2
CAS Registry Number 107868-30-4
SMILES CC12CCC3C(C1CCC2=O)CC(=C)C4=CC(=O)C=CC34C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiovascular disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
OsteoporosisAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
Urogenital disorderAdenylate kinase isoenzyme 1P00568Not Available9456245; 10473018; 14623544; 10514021; 10388095; 9556789; 15814851; 14513432; 11850229; 14687601; 15083379
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast swelling21.05.05.0080.004793%Not Available
Bronchitis22.07.01.001; 11.01.09.0010.004793%
Cardiac failure02.05.01.0010.002501%
Cardiovascular disorder02.01.01.001; 24.03.02.009--Not Available
Carpal tunnel syndrome17.09.02.0010.007189%Not Available
Cataract06.06.01.0010.004793%
Cerebral atrophy17.11.01.0010.004793%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.007189%Not Available
Cerebral ischaemia24.04.06.003; 17.08.01.0050.004793%
Cerebrovascular accident24.03.05.001; 17.08.01.0070.031152%
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.0010.009585%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Choking sensation22.02.05.002; 19.01.02.0020.004793%Not Available
Cholecystitis09.03.01.0010.007189%
Cholelithiasis09.03.01.0020.011982%Not Available
Chromaturia20.02.01.0020.004793%
Chronic obstructive pulmonary disease22.03.01.0070.003126%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.001250%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.001--
Deafness04.02.01.0010.007189%Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
Dementia19.20.02.001; 17.03.01.0010.009585%Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.019171%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.009585%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages